320 related articles for article (PubMed ID: 20719220)
21. Human papillomavirus typing in reporting of condyloma.
Sturegård E; Johansson H; Ekström J; Hansson BG; Johnsson A; Gustafsson E; Dillner J; Forslund O
Sex Transm Dis; 2013 Feb; 40(2):123-9. PubMed ID: 23324975
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus vaccines: current status and future prospects.
Garland SM; Smith JS
Drugs; 2010 Jun; 70(9):1079-98. PubMed ID: 20518577
[TBL] [Abstract][Full Text] [Related]
23. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
[TBL] [Abstract][Full Text] [Related]
25. Models of cervical screening in the era of human papillomavirus vaccination.
Canfell K
Sex Health; 2010 Sep; 7(3):359-67. PubMed ID: 20719228
[TBL] [Abstract][Full Text] [Related]
26. US physicians' intentions regarding impact of human papillomavirus vaccine on cervical cancer screening.
Wong C; Berkowitz Z; Saraiya M; Wideroff L; Benard VB
Sex Health; 2010 Sep; 7(3):338-45. PubMed ID: 20719225
[TBL] [Abstract][Full Text] [Related]
27. [Preventing cancer: The role of Papillomavirus vaccination in the general population].
Vié le Sage F; Cohen R
Bull Cancer; 2020 Jan; 107(1):10-20. PubMed ID: 31982092
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus vaccines: an update for gynecologists.
Ault KA
Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
[TBL] [Abstract][Full Text] [Related]
29. [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].
Six L; Joura EA
Wien Med Wochenschr; 2007; 157(5-6):130-2. PubMed ID: 17427010
[No Abstract] [Full Text] [Related]
30. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.
Brisson M; Van de Velde N; De Wals P; Boily MC
CMAJ; 2007 Aug; 177(5):464-8. PubMed ID: 17709404
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus vaccination: current indications and future directions.
Gattoc L; Nair N; Ault K
Obstet Gynecol Clin North Am; 2013 Jun; 40(2):177-97. PubMed ID: 23732024
[TBL] [Abstract][Full Text] [Related]
32. A brief history of economic evaluation for human papillomavirus vaccination policy.
Beutels P; Jit M
Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
[TBL] [Abstract][Full Text] [Related]
33. Bug breakfast in the bulletin: the early impact of the national HPV vaccination program.
Quinn E; Donovan B; Sheppeard VK
N S W Public Health Bull; 2012 Dec; 23(9-10):208. PubMed ID: 23442998
[No Abstract] [Full Text] [Related]
34. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
36. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
37. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus vaccination and cervical cytology in young minority women.
Brogly SB; Perkins RB; Zepf D; Longtine J; Yang S
Sex Transm Dis; 2014 Aug; 41(8):511-4. PubMed ID: 25013981
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
40. Knowledge of sexually transmitted HPV infection, genitoanal warts, cancer and their prevention among young females after vaccine introduction in Germany.
Kuznetsov AV; Müller RA; Ruzicka T; Herzinger T; Kuznetsov L
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1527-34. PubMed ID: 23216713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
